

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Advanced Nuclear Medicine, LLC</p> <p>2. 2008 West Boulevard Kokomo, IN 46902</p>	<p>In accordance with letter dated June 3, 2013.</p> <p>3. License number: 13-32467-01 is renewed in its entirety to read as follows:</p>	<p>4. Expiration Date: December 31, 2023</p> <p>5. Docket No.: 030-36381 Reference No.:</p>
---	---	---

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Iodine-131 permitted by 10 CFR 35.300	C. Any	C. 500 millicuries total	C. For any use permitted by 10 CFR 35.300, limited to procedures for which the patient can be released under the provisions of 10 CFR 35.75.

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 2008 West Boulevard, Kokomo, Indiana.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-32467-01Docket or Reference Number
030-36381Amendment No. 1
(Corrected Copy)

11. The Radiation Safety Officer for this license is Todd Reyburn, M.D.

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized Users


Todd Reyburn, M.D.

Keith S. Wexler, M.D.

Material and Use

10 CFR 35.100, 35.200 and 35.300, limited to sodium iodide I-131 in quantities not to exceed 33 millicuries

10 CFR 35.100, 35.200 and 35.300, limited to sodium iodide I-131 in quantities not to exceed 33 millicuries



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-32467-01Docket or Reference Number
030-36381Amendment No. 1
(Corrected Copy)

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Letter dated June 3, 2013 excluding request for any byproduct material permitted by 10 CFR 35.300 beyond sodium iodide I-131 in items 5 and 6 (ML13164A357)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

By: Colleen Carol Casey
Colleen Carol Casey
Region 3Date: May 8, 2018